MCP
SLNO

Militia Capital Partners’s Soleno Therapeutics SLNO Stock Holding History

Militia Capital Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.62M Buy
+35,000
New +$1.92M 0.37% 63

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Militia Capital Partners's SLNO Position: Q4 2025 in Review

Militia Capital Partners opened a new position in Soleno Therapeutics (SLNO) in Q4 2025: 35,000 shares worth $1.62M. The stake represents 0.37% of the portfolio and ranks #63 among its holdings.

248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Militia Capital Partners held 35,000 shares of Soleno Therapeutics worth $1.62M as of Q4 2025.
  • Soleno Therapeutics was a new Militia Capital Partners position in Q4 2025.
  • Soleno Therapeutics made up 0.37% of Militia Capital Partners's portfolio in Q4 2025, its #63 holding.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.